hackint0sh/New-Dataset huggingface dataset:
The study is divided into two stages. The first stage will use a "3+3" dose escalation design to explore the safety and tolerability of the investigational drugs. In the second stage, based on the preliminary safety and efficacy results from the first stage, appropriate doses and tumor types will be selected for expansion studies within the safety dose range to further investigate the safety and clinical efficacy of BAT8008+BAT1308 and provide evidence for subsequent clinical studies. conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: BAT8008 injection name: BAT1308 injection measure: Dose-limiting toxicity (DLT) measure: vital signs measure: Physical examination measure: Adverse events measure: Clinical laboratory tests measure: Clinical auxiliary tests measure: Objective response rate (ORR) measure: Duration of Response(DOR) measure: Disease Control Rate (DCR) measure: Progression Free Survival(PFS) measure: Overall Survival(OS) measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic measure: Pharmacokinetic sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341101 id: 2022-503135-33-00 id: 2022-503135-33-00 type: OTHER domain: EU trial number briefTitle: Timely Recovery After Subclinical Heart Failure acronym: TREASURE overallStatus: RECRUITING date: 2024-03-26 date: 2026-03-01 date: 2026-03-01 date: 2024-04-02 date: 2024-04-02 name: Academisch Ziekenhuis Maastricht class: OTHER name: ZonMw: The Netherlands Organisation for Health Research and Development briefSummary: The goal of this randomized controlled trial is to assess the effectiveness of ACE inhibitors versus standard care) in reversing asymptomatic heart failure (HF stage-B) and/or diastolic dysfunction during a two-year open-label treatment period for formerly preeclamptic women on:
Eligible subjects will be counselled and upon informed consent randomized for either medication group (n=65) or care as usual group (n=65). After a complete cardiovascular assessment, medication will be initiated open-labeled (Perindopril 2 mg or no medication). Thereafter, standard medical check-ups (blood pressure, ECG, kidney function, transthoracic cardiac ultrasound, endothelial function, quality of life questionnaires, medical history taking, blood and urine banking) will be performed every six months for two years.
Researchers will compare ACE inhibitor (Perindopril 2 mg) and care as usual (i.e. no medication) to investigate whether ACE inhibitor allows timely recovery after subclinical heart failure. conditions: Heart Failure conditions: Diastolic Dysfunction studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 130 type: ESTIMATED name: Perindopril measure: No left Ventricular Hypertrophy measure: No concentric remodeling measure: No impaired systolic function measure: Normal diastolic function sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AZMaastricht status: RECRUITING city: Maastricht state: Limburg zip: 6202AZ country: Netherlands name: Marc Spaanderman, Prof role: CONTACT phone: +31(0)43-3874145 email: zenab.mohseni@mumc.nl lat: 50.84833 lon: 5.68889 hasResults: False
nctId: NCT06341088 id: B.30.2.ATA.0.01.00/132 briefTitle: Evaluation of Anatomical Results and Sexual Functions After Unilateral and Bilateral Laparoscopic Suture Sacro-hysteropexy Operations overallStatus: RECRUITING date: 2024-04-05 date: 2024-07-05 date: 2024-10-05 date: 2024-04-02 date: 2024-04-02 name: Ataturk University class: OTHER briefSummary: The study was planned as prospective and randomized. For the study, patients will be randomized into two groups as unilateral and bilateral suture sacro-hysteropexy operations. conditions: Pelvic Organ Prolapse studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: unilateral suture sacro-hysteropexy name: bilateral suture sacro-hysteropexy measure: anatomical success of the operations measure: evaluation of the sexual functions of the patients sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Atatürk University status: RECRUITING city: Erzurum state: Palandöken country: Turkey name: Gamze Nur Cimilli Senocak role: CONTACT phone: +905305880025 email: gncimilli@gmail.com lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06341075 id: KY2024-053-02 briefTitle: Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy overallStatus: ENROLLING_BY_INVITATION date: 2024-03-14 date: 2025-03-14 date: 2026-03-14 date: 2024-04-02 date: 2024-04-02 name: Beijing Tiantan Hospital class: OTHER briefSummary: The goal of the real-world study is to evaluate the long-term seizure control outcomes, postoperative complications, long term impact on cognitive, memory function outcomes, quality-of-life measures, and healthcare resource utilization of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) on patients with drug-resistant epilepsy (DRE). conditions: Drug Resistant Epilepsy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) measure: Seizure-freedom rate measure: Seizure frequency reduction measure: ILAE classification of outcome measure: Seizure severity measure: Rate of mild complications measure: Cognitive function evaluation measure: Memory function evaluation measure: The quality of life measure: Length of hospital stay measure: Rate of reoperations measure: Rate of antiepileptic drug reduction or withdrawn sex: ALL minimumAge: 12 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Tiantan Hospital city: Beijing state: Beijing zip: 100070 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06341062 id: M2024078 briefTitle: The Application of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-06-30 date: 2026-06-30 date: 2024-04-02 date: 2024-04-02 name: Peking University Third Hospital class: OTHER briefSummary: The goal of this study is to quantitatively assess renal microcirculation changes by contrast-enhanced ultrasound and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore its predictive value in renal function recovery in patients with critical acute kidney injury. The main questions it aims to answer are:
3. To explore the value of renal microflow changes quantitatively evaluated by contrast-enhanced ultrasound in predicting renal function recovery. conditions: Intensive Care Unit conditions: Acute Kidney Injury conditions: Ultrasound studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 44 type: ESTIMATED name: Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound measure: Serum creatinine values and/or urine output sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Ultrasound Diagnosis, Peking University Third Hospital city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06341049 id: 2024-03/14 briefTitle: Effect of Three Different Postcesarean Analgesic Techniques on QbsQor-10 Score: Prospective, Randomized Trial overallStatus: RECRUITING date: 2024-03-12 date: 2024-06-12 date: 2025-09-12 date: 2024-04-02 date: 2024-04-02 name: Ataturk University class: OTHER briefSummary: The aim of this study is to evaluate the effects of three different postsesarean analgesia techniques, including instillation of local anesthetic into the peritoneum with infiltration into all layers of the anterior abdominal wall, intrathecal morphine injection with local anesthetic, and quadrotus lumborum type 1 block, on the postoperative recovery of women using the ObsQoR-10 score.. conditions: Postoperative Recovery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Intraperitoneal local anasthetic application + local anesthetic wound infiltration name: Intrathecal morphine application name: Quadratus lumborum block tip 1 application measure: obstetric quality of recovery-10 (ObsQoR-10) scores of parturient at the 24th and 48th postoperative hours sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Ataturk University status: RECRUITING city: Erzurum state: Palandoken country: Turkey name: Aysenur Dostbil role: CONTACT phone: +905333676696 email: adostbil@hotmail.com lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06341036 id: Thrombocytosis in Children briefTitle: Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children Hospital overallStatus: NOT_YET_RECRUITING date: 2024-07-15 date: 2025-03-03 date: 2026-03-03 date: 2024-04-02 date: 2024-04-02 name: Assiut University class: OTHER briefSummary: The primary Aim :to determine the etiology of thrombocytosis in children and frequency, outcome of thrombocytosis in Children. conditions: Thrombocytosis in Children studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 42 type: ESTIMATED measure: Aetiology And Outcome Of children with Thrombocytosis admitted to Assiut University children hospital sex: ALL minimumAge: 1 Month maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06341023 id: 2023-1430 briefTitle: Functional Balance Intervention in Multiple Sclerosis acronym: FBIinMS overallStatus: NOT_YET_RECRUITING date: 2024-04-14 date: 2026-01-09 date: 2027-01-09 date: 2024-04-02 date: 2024-04-03 name: University of Illinois at Chicago class: OTHER briefSummary: This project involves two sub-parts:
Each study involves a 2-arm, Phase-1, randomized controlled clinical trial to evaluate the effect of FBI on physical, cognitive function, and daily living among people with MS (PwMS). Study 1 is conducted in a lab setting, while Study 2 is conducted at home with additional safety measures. A total of 150 people with multiple sclerosis will be recruited and telephone screened, with an expected enrollment of 120 (60 per phase). After in-person screening, 96 eligible participants (48 per phase) will undergo pre-training assessment and randomization into FBI or Stretching groups. Training sessions will occur twice a week for four months. Anticipating a 15-17% attrition rate, the target sample size is 80 (40 per phase) for completion of the study. Post-training assessments will be conducted after four months to evaluate FBI's impact on physical and cognitive functions. This evidence-based protocol, previously successful with neurological and older adult populations, intends to provide a low-cost, safe, and effective intervention for PwMS in clinical and community settings, including rural areas. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Subjects will be blinded to group existence and assignment and outcome assessors will be blinded to group assignment whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Functional Balance Intervention name: Stretching measure: Change in physical function measure: Change in cognitive function measure: Change in dual task balance performance measure: Change in dual task gait performance measure: Change in measured community mobility measure: Change in self-reported community mobility measure: Change in self-reported quality of Life measure: Change in walking performance measure: Change in walking speed measure: Change in balance confidence measure: Change in functional independence sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Illinois at Chicago city: Chicago state: Illinois zip: 60612 country: United States name: Tanvi Bhatt, PhD role: CONTACT phone: 312-355-4443 email: tbhatt6@uic.edu name: Rudri Purohit, MS role: CONTACT phone: 3128773640 email: rpuroh2@uic.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06341010 id: The Role of Angiojet Rheolytic briefTitle: The Role of Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-01-01 date: 2026-09-01 date: 2024-04-02 date: 2024-04-02 name: Abdelrahman Ibrahim Sayed Mohamed Abdalla class: OTHER briefSummary: The aim of this study is to evaluate the efficacy and safety of rheolytic thrombectomy in restoring venous patency DVT, periprocedural complications and development of PTS after tratment of iliofemoral DVT. conditions: Iliofemoral Deep Vein Thrombosis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis measure: Technical success measure: Incidence of PTS sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06340997 id: Mitral Stenosis briefTitle: Impact of Percutaneous Transvenous Mitral Commissurotomy on The Left Atrial Appendage Function in Patients With Mitral Stenosis. overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-10-01 date: 2027-08-01 date: 2024-04-02 date: 2024-04-02 name: Assiut University class: OTHER briefSummary: • Evaluation of the effect of PTMC on LAA function by TEE at least one month after the procedure and its effectiveness in prevention of thrombi formation and cerebrovascular complications. conditions: Mitral Stenosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 25 type: ESTIMATED name: Transesophageal echocardiography measure: Impact of Percutaneous Transvenous Mitral Commissurotomy on The Left Atrial Appendage Function in Patients with Mitral Stenosis. measure: Prevention of left atrial appendage thrombus. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340984 id: sICAM-1 in acne vulgaris briefTitle: Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-11 date: 2025-02 date: 2024-04-02 date: 2024-04-03 name: South Valley University class: OTHER briefSummary: The aim of this study is to:
3. Evaluate the effect of Montelukast on serum (sICAM-1) level in acne vulgaris conditions: Acne Vulgaris studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Montelukast 10 Mg Oral Tablet measure: Evaluation of serum soluble intercellular adhesion molecule-1 (sICAM-1) level in acne vulgaris (moderate -severe ) measure: Montelukast in treatment of acne vulgaris patients sex: ALL minimumAge: 15 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06340971 id: 331247 briefTitle: Air Pollution and Pregnancy acronym: PTB overallStatus: RECRUITING date: 2024-09-01 date: 2029-08-31 date: 2029-08-31 date: 2024-04-02 date: 2024-04-02 name: Queen Mary University of London class: OTHER name: University College London Hospitals briefSummary: We are an inter-disciplinary team of UK scientists with expertise in obstetrics, women's and child health, epidemiology, climate science, inflammation, computational modelling, machine learning and artificial intelligence. Together we have a long history with existing strengths underlying preterm birth research that crosses multiple disciplines and an excellent track record of publications and awards leading research in preterm birth.
We aim to develop and validate a deep learning model to predict the risk of preterm birth and other adverse pregnancy outcomes using data from EPIC electronic health records at University College London Hospital Trust (UCLH) for a cohort of 18000 patients. We will obtain corresponding data on exposure to ambient pollution using non-identifiers for postcode (area) and date of delivery (month). The model will review the temporal sequence of events within a patient's medical history and current pregnancy, identifying significant interactions and will predict the risk of preterm birth. It will also determine the threshold and gestation at which pollution exposure has the greatest impact. conditions: Premature Birth studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 200000 type: ESTIMATED name: Policy measure: Machine learning model to predict the risk of preterm birth and adverse birth outcomes measure: Machine learning model to predict how air quality increases the risk of preterm birth and adverse birth outcomes sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tina Chowdhury status: RECRUITING city: London zip: E14NS country: United Kingdom name: Tina Chowdhury role: CONTACT phone: 0207882 phoneExt: 7560 email: t.t.chowdhury@qmul.ac.uk name: Rhona Atkins role: CONTACT phone: 0207882 phoneExt: 7272 email: rhona.atkin@nhs.net lat: 51.50853 lon: -0.12574 facility: Anna David status: RECRUITING city: London zip: NW1 2PG country: United Kingdom name: Yaa Acheampong role: CONTACT phone: 020 3447 phoneExt: 6164 email: y.acheampong@nhs.net name: Anna David role: CONTACT phone: 0203 447 phoneExt: 9400 email: a.david@nhs.net lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06340958 id: CLE100-MDD-202 briefTitle: A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder acronym: SOLEO overallStatus: RECRUITING date: 2024-03-18 date: 2025-07-11 date: 2026-01-10 date: 2024-04-02 date: 2024-04-10 name: Clexio Biosciences Ltd. class: INDUSTRY briefSummary: The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the treatment of MDD in participants currently treated with an oral antidepressant medication and who have an inadequate response to at least 2 antidepressants. conditions: Adjunctive Treatment of Major Depressive Disorder (MDD) studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 90 type: ESTIMATED name: CLE-100 name: Placebo measure: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score measure: Change from Baseline in the Clinical Global Impression - Severity (CGI-S) measure: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) score measure: Safety Outcomes: Assessment of the safety and tolerability of CLE-100 compared to placebo sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Site 105 status: RECRUITING city: Lauderhill state: Florida zip: 33319 country: United States lat: 26.14036 lon: -80.21338 facility: Clinical SIte 112 status: RECRUITING city: Miami Lakes state: Florida zip: 33016 country: United States lat: 25.90871 lon: -80.30866 facility: Clinical Site 118 status: RECRUITING city: Atlanta state: Georgia zip: 30030 country: United States lat: 33.749 lon: -84.38798 facility: Clinical Site 128 status: RECRUITING city: Marlton state: New Jersey zip: 08054 country: United States lat: 39.89122 lon: -74.92183 facility: Clinical Site 101 status: RECRUITING city: Toms River state: New Jersey zip: 08755 country: United States lat: 39.95373 lon: -74.19792 hasResults: False
nctId: NCT06340945 id: S2023-761-01 briefTitle: The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-12-31 date: 2029-12-31 date: 2024-04-02 date: 2024-04-02 name: Chinese PLA General Hospital class: OTHER briefSummary: 1. To evaluate the clinical outcomes of ultrasound-guided thermal ablationfor the treatment of benign thyroid nodules;
2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of benign thyroid nodules conditions: Thyroid Nodules studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 1500 type: ESTIMATED name: ultrasound-guided thermal ablation measure: volume reduction rate measure: rate of nodule regrowth measure: rate of complications measure: cosmetic score measure: symptom score measure: vital volume measure: total volume sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340932 id: CRS-119 (Pro00077191) briefTitle: Impact of Opioid Avoidance Protocol for ACL Reconstruction overallStatus: NOT_YET_RECRUITING date: 2024-03-28 date: 2024-08-15 date: 2024-10-01 date: 2024-04-02 date: 2024-04-02 name: Matthew Varacallo class: OTHER name: Pacira Biosciences briefSummary: This is a prospective, quasi-experimental, cohort study comparing patients treated with one of two postoperative pain management protocols. The two protocols assessed will be the current standard of care protocol for ACLR postoperative pain control utilized by Dr. Matthew Varacallo and then an opioid avoidance protocol that is planned to be implemented on the Spring of 2024. The study is voluntary, however all patients will be treated with either of the two protocols depending on their date of surgery. This study will include patients aged 15 years and older who consent to the participation in the study. Patients will be identified utilizing the operative surgeon's appointment calendar and will be screened and offered inclusion in the study if applicable at their pre-operative visit. Data will be collected via patient medication and pain diary, phone call, and clinician administration of standardized outcome questionnaires. Patients will be included in the standard of care group if ACLR is performed prior to the change in protocol in the Spring of 2024 or the opioid avoidance group if performed after the protocol change.
* assess KOOS pain and symptom scales at 8 weeks post-operatively between groups. conditions: ACL Tear conditions: Post Operative Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Iovera name: Celecoxib name: Acetaminophen name: Oxycodone name: Tramadol name: Bupivacaine Hydrochloride name: Acetaminophen 500Mg Cap measure: Opioid consumption from POD0-POD7 measure: Average daily pain (NRS) measure: Average daily worst pain (NRS) measure: KOOS Pain Subscale Score measure: Quality of Recovery-15 measure: Pittsburgh Rehabilitation Participation Scale Score sex: ALL minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Penn Highlands Dubois city: DuBois state: Pennsylvania zip: 15801 country: United States name: Samantha Morgan, DAT role: CONTACT phone: 814-496-3141 email: slmorgan@phhealthcare.org name: Christopher Varacallo role: SUB_INVESTIGATOR name: Samantha Morgan role: SUB_INVESTIGATOR lat: 41.11923 lon: -78.76003 hasResults: False